Clinical Trial

CUE-102 in Recurrent Glioblastoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-07; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Recruiting 2025-06-11
Trial Details
NCT Number NCT06917885
Lead Sponsor David Reardon, MD
Collaborators: Cue Biopharma
Conditions Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant
Enrollment 18 participants
Start Date 2025-07-30
Primary Completion 2027-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-05